Podcasts about Inflection point

In this episode: success on paper, building the life you want, therapy, craving progression, and what leads to change. When beginning and well into your FI journey, it may seem like reaching and achieving your end goal of financial independence will somehow leave you feeling happier and more fulfilled. However, reaching this end goal doesn't automatically solve all your problems. On this week's episode we are joined by founder of FindMoreBalance.com and host of "The Mental Wealth Show" Rich Jones to have a conversation about mental health, rebuilding mindset and behaviors, and importance of finding your network of support in life. The FI journey is a great one because it allows you to introduce changes into your life, and no matter how big or different the changes are, they are still significant! The best part of this journey is that it is a personal one, so try to remember that! While the end goal may be reaching a monetary number, it is also about rebuilding and progressing into the person you want to be in all areas of life! Rich Jones: Website: richrunstrack.com Podcast: The Mental Wealth Show Instagram: @richrunstrack LinkedIn: Rich Jones Timestamps: 4:12 - Introduction 5:36 - Success On Paper 12:31 - The Inflection Point, What Made You Change? 16:14 - Therapy 20:54 - Re-Finding The Person You Want To Be 27:38 - Craving Progress And Mastery 35:11 - Rebuilding Your Day-To-Day Life 43:50 - Leveraging Your Career To Get More From Life 52:21 - Conclusion Resources Mentioned In Today's Episode: LeaveUs A Voicemail For Your Year End Wins The Top Chase Business Credit Cards for 2022 Alignment & Adjustments | Scott & Taylor Rieckens | ChooseFI Ep 403 The Tail End Subscribe to The FI Weekly! More Helpful Links and Resources: Earn $1,000 in cashback with ChooseFI's 3-card credit card strategy Share FI by sending a friend ChooseFI: Your Blueprint to Financial Independence Keep learning or start a new side hustle with one of our educational courses Commission-Free Investing with M1 Finance

(Due to a production error, the original episode was removed today. Please enjoy this corrected version of the episode.) Stigall wonders if Elon Musk is leading the marketplace kicking and screaming to relent on its persecution of conservatives? From CNN, to Disney, to Apple and Twitter - things seem to be shifting rapidly and Democrats are screaming loudest in disapproval. Julie Kelly returns to discuss the state of the January 6th detainees and the prosecution of some of the "Oath Keepers" in D.C. And Dr. Sebastian Gorka as a loyal former advisor to Donald Trump sets the record straight as he sees it on Kanye, DeSantis, and Trump's future as the possible nominee for Republicans in 2024.

The biogas/biomethane industry is now one of the promising segments of the Energy Transition: security of supply, renewables sources, local jobs, round the clock dispatchability; the industry ticks all boxes.Biogas can basically be made from any organic material, so the three big sectors are: 1) agricultural wastes (manures and slurries, crop residues) 2) food waste (from the processed food industry or food manufacturing, but also from supermarkets and households) 3) waste water. Biogas only contains 50%-60% methane; it can be upgraded to produce “biomethane” by removing the CO2 and other impurities.Recent massive deals have made the headlines (BP acquisition of Archaea, Shell of Nature Energy, Macquarie of BayWa biogas, Nextera of Energy Power Partners) and more big players are committing capital to this industry: (TotalEnergies, Marubeni). Overall, the industry could x10 this decade.To discuss the future of biogas/biomethane, we bring on Chris Huhne, UK Energy and Climate Change Secretary from 2010 to 2012, one of the founding fathers of CFDs in the Renewable Energy Industry and currently Chair of ADBA (Anaerobic Digestion and Bioresources Association).We review the challenge of technological standardisation, government incentives, and feedstock supply chains. Will biogas solve the energy transition on its own? Certainly not. Will it be an important part of the solution? Definitely.We thank our long-time partners Aquila Capital

Stigall wonders if Elon Musk is leading the marketplace kicking and screaming to relent on its persecution of conservatives? From CNN, to Disney, to Apple and Twitter - things seem to be shifting rapidly and Democrats are screaming loudest in disapproval. Julie Kelly returns to discuss the state of the January 6th detainees and the prosecution of some of the "Oath Keepers" in D.C. And Dr. Sebastian Gorka as a loyal former advisor to Donald Trump sets the record straight as he sees it on Kanye, DeSantis, and Trump's future as the possible nominee for Republicans in 2024.

Canagold Resources Ltd (TSX:CCM)(OTCQB:CRCUF) CEO Catalin Kilofliski speaks to Proactive at the 2022 edition of Resourcing Tomorrow, brought to you by Mines and Money. He suggests that there is ‘light at the end of the tunnel' for the gold market and explains his vision for the future of the company.

In this episode, Jason Foster talks to Allison Sagraves, Portfolio Chief Data Officer, Board Advisor, Adjunct Faculty at Carnegie Mellon University and former Chief Data Officer of M&T Bank. They talk about providing value with data, strategic prioritisation in data, how to align success criteria with business objectives, data culture and building well-rounded data teams.

John Kosar, chief market strategist at Asbury Research, says that the market has reached a key point, and he believes the lows the market made in June and retouched in October -- in the 3,500 range for the standard & Poor's 500 -- will stick, and last several quarters. He remains positive on the market for now, noting that his key indicators remain green, but notes he won't be surprised if the market re-tests those lows before moving forward again in 2023. Also on the show, Amanda Agati, chief investment officer at PNC Asset Management, discusses the rising cost of the "12 Days of Christmas," noting that inflation in the firm's Christmas Price Index is running even higher than inflation elsewhere in the economy, and how that reflects current events and broad economic conditions, author Paul Tucker discusses his new book, "Global Discord: Values and Power in a Fractured World Order" and, in the Market Call, Hank Smith, head of investment strategy at The Haverford Trust Co., discusses large-cap companies with a history of paying/raising dividends.

US inflation data came in lower than expected. Our analysts discuss the broader trend, and if the US will slow rate hike. And as Malaysia goes to the polls this Saturday, we look into the impact on markets in this tight race. 00:22 - Roundup - Chua Hak Bin 04:21 - US bond yields - Winson Phoon 06:42 - ASEAN bonds - Winson 07:34 - USD inflection - Saktiandi Supaat 10:05 - MYR appreciation - Saktiandi 11:47 - MY GDP drivers - Suhaimi Ilias 14:42 - MY GE - Suhaimi 16:11 - ID GDP - Lee Ju Ye 18:22 - ID interest rate - Ju Ye 19:12 - PH GDP - Zamros Dzulkafli 22:56 - ASEAN picks - Anand Pathmakanthan 25:54 - MY picks, GE - Anand 26:49 - CPO prices - Ong Chee Ting 30:04 - Plantation picks - Chee Ting Producer: Noelle Lim, Maybank IBG

Viewpoint This Sunday with Malcolm Out Loud – With the House, Senate, Gubernatorial and local races… Attorney Sidney Powell talks about election fraud at the midterms. Pres Biden said the biggest threat to democracy is MAGA Republicans. A new poll says the media is a bigger 'threat to democracy.' Dinesh D'Souza talks about the president's speech and impact on the midterms. Dr. Elizabeth Lee Vliet on the FBI Whistleblower story as we celebrate Viewpoint This Sunday's 5 year annviersary...

Viewpoint This Sunday with Malcolm Out Loud – With the House, Senate, Gubernatorial and local races… Attorney Sidney Powell talks about election fraud at the midterms. Pres Biden said the biggest threat to democracy is MAGA Republicans. A new poll says the media is a bigger 'threat to democracy.' Dinesh D'Souza talks about the president's speech and impact on the midterms. Dr. Elizabeth Lee Vliet on the FBI Whistleblower story as we celebrate Viewpoint This Sunday's 5 year annviersary...

Anton answers live questions from viewers like you on the topics of trading, investing, finance, options, and more! Ask your live questions every weekday at noon central time!

Anton answers live questions from viewers like you on the topics of trading, investing, finance, options, and more! Ask your live questions every weekday at noon central time!

At long last, we reach the end of the very early church's first decade. We'll conclude this complex and dense time period by looking at two of Peter's miracles, including a very rare one. Then, we'll answer the seven questions with which we sum up each decade's qualities.

In episode 21of ReBootHealth, I speak with Sanjana Basu, Investor at Radical Ventures. In her time at Radical, Sanjana has focused on AI/ML innovation across multiple sectors including health. We all know that this is a hot area and see its eventual value in healthcare, so I wanted to get a sense of where we are in this journey, especially as the capital markets take a breather. With that as background, we talked about Canada's continued role in AI/ML in healthcare, the foundational underpinnings of the sector, what investors in the space look for in ventures, managing the market reset, and future opportunities in the space. As always, I hope you find the episode valuable. Please write a review on Apple Podcast. For other episodes or to learn more you can visit us at ReBootHealth or follow us on Twitter: @Reboothealth1 Episode recorded on September 28, 2022. 07:37—Canada's opportunities and challenges for AI/ML in healthcare. 12:50—A path to move ahead in AI/ML and healthcare. 19:50—The waves of AI/ML in health. 27:30—Level setting between media ‘hype' and reality. 31:00—Investors and the need for second-level thinking. 43:30—Preparing your venture for a successful capital raise reset. 56:40—Assessing the risks of AI/ML health ventures. 1:01:35—Future opportunities in the space. Building a Learning Health System for Canadians Adoption Imperative Part I: Digital Health's Inflection Point

The Sunday Times' tech correspondent Danny Fortson brings on Marcus Gerhardt, chief executive of Blackrock Neurotech, to talk about his boarding school days in Wales (4:00), his dotcom adventures (10:00), pivoting to brain-computer interfaces (16:00), the “Utah array” (18:40), how in 2006 the first person sent an email with his thoughts (20:30), starting the company (23:00), the state of the technology today (26:40), targeting tetraplegics (33:00), getting investment (38:15), going to market (41:30), and reaching an inflection point (47:40). Hosted on Acast. See acast.com/privacy for more information.

The annual Conference of the Parties —a global meeting of negotiators and heads of state to discuss a path forward on climate action—is coming up in a little over a week. Historically these meetings gin up all sorts of climate disinformation. Today, a new report walks journalists and other communicators through the many ways they can counter disinfo without amplifying it. Report: https://caad.info/report/journalist-field-guide-navigating-climate-misinformation/

Ashley and Stephanie Lepp sit down with Nore Bateson to discuss warm data, nursing mothers, balance bikes, and what all that has to do with the sustainable development goals (if anything!). Nora Bateson is a filmmaker, lecturer, author. Founder of #WarmData #PeopleNeedPeople #symmathesy #aphanipoiesis. Ecology & society reframing & shifting perception, complexity, and tenderness. Stephanie Lepp, producer and conceptual artist. I'm the outgoing Executive Producer at the Center for Humane Technology, and incoming Executive Director at the Institute for Cultural Evolutions. To get a feel for Stephanie's work, listen to her interviews on The Jim Rutt Show (jimruttshow.com/stephanie-lepp/) and KALW's Inflection Point (bit.ly/3jGcAEg). The best way to be in dialogue with Stephanie is to follow her on Twitter: @stephlepp Ashley Colby is an Environmental Sociologist who studied at Washington State University, the department that founded the subdiscipline. She's interested in and passionate about the myriad creative ways in which people are forming new social worlds in resistance to collapse. She's the founder of Rizoma Field School in Colonia Uruguay.

The Kansas Jayhawks finish out their road trip down in Waco, TX as they take on the Baylor Bears before the bye week. To help preview the matchup, Andy is joined by Matt Wilson of Our Daily Bears and the Between Two Bears podcast to break down everything Baylor. They talk about the disappointing results for this team, how Blake Shapen has lived up to expectations, and why the running game seems to have taken a step back. Plus, they look at the defensive losses, how they can try to stop Kansas, and then get into picks and predictions. And of course, they had to end with just a bit of basketball talk.Follow Andy on Twitter: @AndyMitts12Follow Matt on Twitter: @mattisbearFollow Blue Wings Rising on Twitter: @bluewingsriseWe want your input on the podcast. If you have something you would like to talk about on the podcast, or any suggestions for people that we should try to talk to, let us know by emailing us at rockchalkpodcast@gmail.com or on twitter @RockChalkPod.Get the most comfortable vintage college sports t-shirts, sweaters, hoodies and more at Homefield Apparel! With more than 100 schools available (and new ones added all the time) you are sure to find something that you'll absolutely love. Promo code "CHALK12" gets you 15% off your first order at https://www.homefieldapparel.com/, and all orders $100 or more get free shipping.Join in the easiest legal way to play daily fantasy with PrizePicks. Through their award winning, easy to use mobile app, you can quickly pick on props for your favorite events across the sports world, including NFL, MLB, NBA, Soccer, College football and basketball and more! Use promo code Chalk12 at sign up and get an instant 100% match on your first deposit up to $100. Get more info at https://bit.ly/Chalk12.A proud part of the Ten12 Podcast Network on Sports Drink. Find links to all of our great shows on our Twitter account at @Ten12Network.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt Spielman is Founder of Inflection Point Partners and author of the newly released book, Inflection Points-How To Work and Live With Purpose. (Check out a quick one sheeter here as well.)  Matt notes, "I transitioned from Executive to Executive Coach . . . and the part that really drew me in was seeing the people on the team grow, develop, thrive, giving them stretch opportunities, the promotion discussions and . . . just giving feedback in a constructive way. That was the stuff that really drew me in." He discusees his own (rather inspirational!) career journey, what he went through himself at 44, finding sources and drains of energy, some of the concepts behind what he calls the Game Plan System ("you can't goal set your way out of an emotional rut"), and more.  He goes on to chat about the effect COVID has had (in both positive and negative ways) on people's lives and career paths, and how he built his own coaching practice from scratch. (It was a slow, steady climb, and now Spielman counts executives like Alex Rodriguez and Bill Owens, Executive Producer for 60 Minutes, as some of his clients.)  Matt received his MBA from Harvard Business School, and a BA from Columbia University, where he earned national honors as a varsity baseball player.  Matt has been a friend of Integrity Square for many, many years and we wish him all the best on the launch of his book and the continued growth of Inflection Point Partners! Click here to download transcript. 

Browns safety John Johnson III indicated on Wednesday that some Browns players need to do a better job of taking their work home with them, making sure they were putting in the extra time to get things turned around. Other players have also put it on them and their teammates to get this seasons pointed in the right direction. Have we already reached an inflection point? Will we look back at this week and say it was when things turned around or when they really went south? Mary Kay Cabot, Ashley Bastock and Dan Labbe discussed that as well as what it means if the Browns don't have Wyatt Teller on Sunday and look at some other injured players whose statuses they're keeping an eye on for this week. Want to get involved in Football Insider? Click here for more info and to sign up. Music credit: Ice Flow by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3898-ice-flow License: https://filmmusic.io/standard-license Learn more about your ad choices. Visit megaphone.fm/adchoices

We talk a lot about impact investing on this show, and while we tend to focus on the deals and the companies, we often gloss over the more challenging process of impact measurement and management. Right now is an important time to explore these issues, because the structures of impact investing are at an inflection point. The market has realised the importance of using consistent systems, and the frameworks are starting to consolidate, they're harmonising. Today we have Dean Hand on the show to help us explore impact measurement and management, she's Chief Impact Officer at the GIIN (the Global Impact Investment Network), and she's had long experience with impact reporting, both at the GIIN, which is a pivotal player in developing these impact measurement and management systems. In this episode Dean explains both the origins and the utility of the leading frameworks that the GIIN manages. But we also explore the broader alphabet soup of frameworks, standards and principles that are out there. And, on this important topic, I want to take the research further. So I'm going to take the insights from this episode with Dean, and from the next few episodes with other leading practitioners, and pull it all together into a special report. It'll have input from global leaders in the space, with case-studies highlighting leading practice in the market. It should be out soon, but if you don't want to miss it sign up for my newsletter, and you'll get it in your inbox as soon as it's released. You can sign-up on my website at www.johntreadgold.com and of course that's where you'll find all the show notes from the podcast, and all my other various writings and work. Enjoy!

Security Traders Association President and CEO Jim Toes joins Chris and Kurt to unpack key themes from the STA's 89th Annual Market Structure Conference in Washington, D.C., including crypto regulation, best execution, “gamification,” payment for order flow and other market plumbing issues. Learn more about the STA here: https://securitytraders.org/. 

Browns safety John Johnson III indicated on Wednesday that some Browns players need to do a better job of taking their work home with them, making sure they were putting in the extra time to get things turned around. Other players have also put it on them and their teammates to get this seasons pointed in the right direction. Have we already reached an inflection point? Will we look back at this week and say it was when things turned around or when they really went south? Mary Kay Cabot, Ashley Bastock and Dan Labbe discussed that as well as what it means if the Browns don't have Wyatt Teller on Sunday and look at some other injured players whose statuses they're keeping an eye on for this week. Want to get involved in Football Insider? Click here for more info and to sign up. Music credit: Ice Flow by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3898-ice-flow License: https://filmmusic.io/standard-license Learn more about your ad choices. Visit megaphone.fm/adchoices

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

The 20th Party Congress of the Chinese Communist Party, which kicked off on Sunday, promises to be one of the most significant events for China in modern history, not only because President Xi Jinping is widely expected to secure an unprecedented third term, but also because it comes amid the country's slowest pace of growth in decades. So, whether the Congress marks an inflection point for economic policy is Top of Mind. In the latest episode of Exchanges at Goldman Sachs, Susan Shirk, chair of the 21st Century China Center at UC San Diego, David Li, professor at Tsinghua University, and Hui Shan, Goldman Sachs Research' chief China economist, discuss what to watch for that could presage a policy inflection, what that inflection may look like, and what it could mean for growth. This episode is based on GIR's Allison Nathan's latest Top of Mind report.

Coming off of a weekend without Penn State Football, Tom & Andy take the opportunity to reflect the season so far, commenting on some of the pleasant surprises and speculating about what they think might lay ahead. Then they dissect the upcoming matchup against Michigan, a top-ten clash that in many ways will decide the trajectory of the rest of the season.

For the 98th episode of the Healthcare IT Podcast, we're joined by a special guest host, Anders Brown, Managing Director at Tegria. It was awesome to be able to sit down with Anders Brown to get his first hand experiences dealing with the topic we are discussing in this episode: healthcare's inflection point and the […]

Hosts John Lynn and guest host, Anders Brown discuss Healthcare's Inflection Point and the Way Forward. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

The 11th episode of Season 6 on Roast! West Coast features garagepreneur Andrew Scott, Founder, Head Coffee Roaster at Inflection Point Coffee in San Diego, CA. Find Inflection Point Coffee at local San Diego farmers markets and online at inflectionpoint.coffee. R!WC industry partner First Light Whiskey wants you to try their coffee whiskey. Listeners get 15% off at Barbank.com. Use Discount Code: RWC to get 15% OFF your First Light Whiskey Order. Head to www.firstlightwhiskey.com to learn more about the brand and follow @firstlightwhiskey on Instagram. Support this show by SUBSCRIBING to the newsletter and choosing the paid subscription at: https://roastwestcoast.substack.com/subscribe Head to www.roastwestcoast.com for show recaps, coffee education, guest list and coffee news. Follow us on Instagram: @RoastWestCoast or Facebook: @RoastWestCoast ROAST! West Coast is one of the premier entrepreneurial podcasts that features interviews coffee professionals and coffee education. Host Ryan Woldt interviews roastery founders, roasters, coffee shop experts, farmers, green coffee brokers and more about their coffee origin stories, how they've dealt with the impacts of Covid-19, why they love coffee and much more. If you love coffee, entrepreneurship, shopping local, learning how things get made and why things are done a certain way you will love ROAST! West Coast presented by One Wild Life Co. We dive deep into the coffee industry with the help of Industry Legacy Partners including: Ascend Roasters, Ignite Coffee Company, Steady State Roasting, Zumbar Coffee & Tea, Marea Coffee, Mostra Coffee, Cafe LaTerre, First Light Whiskey, Camp Coffee, and Cape Horn Coffee. Support Women's reproductive rights with a donation to the National Network of Abortion Funds here: https://abortionfunds.org/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/roastwestcoast/support

Dry January is long over and Sober September is nearing its' end, but the sober curious movement is here to stay.  The non-alcoholic beer industry has grown at a rapid rate and is projected to reach over $30 billion by 2030. Bill Shufelt, Founder of Athletic Brewing Company is at the forefront of this growth. He joined us on the Inflection Point to share how his experience with sobriety led to the creation of Athletic Brewing Company, the stigma around not consuming alcohol, and the mega trends that have contributed their success. Note to All Readers: The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this podcast. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this podcast. This podcast is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer or solicitation for the purchase or sale of any financial instrument, product or service sponsored by AllianceBernstein or its affiliates. The [A/B] logo is a registered service mark of AllianceBernstein, and AllianceBernstein® is a registered service mark, used by permission of the owner, AllianceBernstein L.P. © 2020 AllianceBernstein L.P.

Lynne Twist, the author of “The Soul of Money,” joins Skye and Emily to talk about her work with The Pachamama Alliance in preserving the Amazon rainforest. Through engaging workshops and immersion programs, The Pachamama Alliance seeks to create a critical mass of conscious commitment to create a better world.   In this interview, Lynne shares a message of hope as we look to the future. She discusses the “3 myths of scarcity” and ways we can avoid these negative cycles. Instead of dreading the future's uncertainty, she suggests letting gratefulness overflow in our hearts until it spills out to the people around us. You won't want to miss Lynne's positive energy.   For more information about the 6AMERS community, you can visit: https://the6amers.com/ Follow us on Instagram for a daily dose of inspiration: https://www.instagram.com/the6amers/

A high energy and story-filled conversation with Denver-based consultant and coach Alecia Huck on common leadership challenges when a small business grows beyond its comfort zone. As Alecia puts it, "bigger is different." Her experience helping leaders successfully navigate growth brings with it a lot of great lessons for life and business. We also cover Alecia's path to founding her company, Maverick and Company, almost twenty years ago. (The mentoring network for veterans that was mentioned in the episode is here: https://www.veterati.com.)

As the US dollar index breaches 20-year highs, many foresee an imminent cyclical devaluation, although rumours of the demise of the dollar as the de-facto global currency look premature.  By Argus Chief Economist, David Fyfe

PLEASE subscribe to my SGT Report RUMBLE channel (Thanks!!): https://rumble.com/c/SGTReport   Robert Beadles is a Patriot whose family lineage goes all the way back to Benjamin Franklin. Beadles continues to work for and fight for election integrity, and he and I agree: We are at the ultimate inflection point in American history. It's now or never to take our country back from the demons who are stealing it.   WATCH this episode HERE: https://rumble.com/v1i1krn-this-is-the-inflection-point-in-american-history-robert-beadles.html

Join Marty as he sits down with London Paul to discuss if the world is heading toward an inflection point, whether the inflation reduction act is a point of no return and what does the endgame for the state of the world look like. Follow London Paul on Twitter Check out The Sirius Report Shoutout to our sponsors: Unchained Capital Braiins HodlHodl Upstream Data TFTC Merch is Available: Shop Now Join the TFTC Movement: Main YT Channel Clips YT Channel Website Twitter Instagram Follow Marty Bent: Twitter Newsletter Podcast

Public asset owners are at an inflection point as traditional investment strategies and business models are challenged by a rapidly changing landscape. Sovereign funds, public pension funds and central banks, which collectively hold over $40tn in assets, need to adapt to an industry in flux to achieve their core goals. In a far-reaching, survey-based report, ‘The Evolution of Public Asset Owners', BNY Mellon finds that the majority of public asset owners are seeking new and bold ideas in search of yield, that only 6% are satisfied with their business models and a solid majority have begun operational transformation, in large part to meet the demands of digitisation and data challenges. Christine Mikolajuk, Europe, Middle East and Africa chief operating officer for global client management at BNY Mellon, joins Patricia Haas Cleveland, OMFIF US president, to discuss the report's findings.

Diamcor Mining: (TSX.V: DMI | OTCQB: DMIFF) Website: https://www.diamcormining.com/ Contact: Mr. Rich Matthews rmatthews@integcom.us +1 (604) 757-7179 Diamcor Mining Inc. is a fully reporting publically traded junior diamond mining company which is listed on the TSX Venture Exchange under the symbol V.DMI, and on the OTC QB International under the symbol DMIFF. The Company has a well-established prior operational and production history in South Africa, extensive prior experience supplying rough diamonds to the world market, and has established a long-term strategic alliance with world famous Tiffany & Co. Rather than exposing itself to the high risks and costs associated with traditional exploration, the Company's focus is on the identification, acquisition, and operation of unique diamond projects with near-term production potential such as the Krone-Endora at Venetia Project. The Krone-Endora at Venetia project was acquired from De Beers and is co-located directly adjacent to the De Beers Venetia Diamond Mine in the Limpopo province of the Republic of South Africa, approximately 500 km north-northeast of Johannesburg. The Venetia mine is the 3rd largest diamond mine in the world, and South Africa's largest producer of diamonds, accounting for over 50% of South Africa's annual output. A high percentage of the diamonds produced at Venetia are reported as being gem quality, with the rest sold for industrial uses. Given the Krone-Endora projects location directly adjacent to the established Venetia mine, many operational benefits are obvious. In addition to this, both the previous exploration and the NI43-101 report concluded that the deposit on Krone-Endora at Venetia was not only an alluvial deposit, but also a rare eluvial deposit indicating a direct shift of material from the higher grounds of the Venetia Kimberlite clusters onto the lower surrounding areas of Krone-Endora. Given the eluvial nature of the deposit and its location directly adjacent to the source, the diamondiferous gravels at Krone-Endora at Venetia appear much more consistent in nature with initial grades from drilling and bulk testing much higher than that of typical alluvial type deposits. As part of the acquisition process an independent NI 43-101 technical report for the Krone-Endora at Venetia project was released by the Company in July of 2009 and updated in April of 2015. The updated report provided an inferred resource estimate of 57,981,000 tonnes of diamond-bearing gravels with 1,387,000 carats of diamonds for the areas of the project on which work has been done to date. In conjunction with a planned move to immediate trial-mining exercises on these areas, the Company will concurrently perform additional drilling to determine the full potential of the project to assist in final production decisions. The deposit is also noted to be near surface, and diamond bearing from surface to bedrock, and with a total depth of 15 meters from surface to bedrock, will allow for a simple, low-cost strip mining operation to be employed. Website | www.provenandprobable.com Call me directly at 855.505.1900 or email: Maurice@MilesFranklin.com Precious Metals FAQ - https://www.milesfranklin.com/faq-maurice/ Proven and Probable Where we deliver Mining Insights & Bullion Sales. I'm a licensed broker for Miles Franklin Precious Metals Investments (https://www.milesfranklin.com/contact/) Where we provide unlimited options to expand your precious metals portfolio, from physical delivery, offshore depositories, and precious metals IRA's. Call me directly at (855) 505-1900 or you may email maurice@milesfranklin.com. Proven and Probable provides insights on mining companies, junior miners, gold mining stocks, uranium, silver, platinum, zinc & copper mining stocks, silver and gold bullion in Canada, the US, Australia, and beyond.

Here's what industry execs were worried about at the Farnborough Airshow. Guests include:  Bradley Peniston, Defense One Deputy Editor; Marcus Weisgerber, Defense One Global Business Editor; Andrew Hunter, assistant secretary of the U.S. Air Force for acquisition, technology and logistics; Raytheon CEO Greg Hayes; Bell Helicopter CEO Mitch Snyder; And Eric Chewning, of the consulting firm McKinsey's aerospace and defense practice.

Watch Bishop T.D. Jakes from The Potters Touch To support this ministry financially, visit: https://www.lightsource.com/donate/973/29

You need to reach the point of inflection. Inflection is the point where true transformation takes place, a point of no return. To support this ministry financially, visit: https://www.lightsource.com/donate/973/29

You need to reach the point of inflection. Inflection is the point where true transformation takes place, a point of no return. To support this ministry financially, visit: https://www.lightsource.com/donate/973/29

Watch Bishop T.D. Jakes from The Potters Touch To support this ministry financially, visit: https://www.lightsource.com/donate/973/29

In this episode, Bradley and Scott sit down with industry expert and author of Inflection Point, Troy Korsgaden. The guys discuss the similarities between the restaurant industry and insurance, the direction the industry is headed, and Troy's new book. Plus, Scott shares the secret of making a fortune in the cattle business. Want More Info On The 2023 One City World Tour? Visit onecityworldtour.com ///////////// Sponsor: GloveBox A seamless all-in-one platform connecting clients to your agency and their carriers. Maximize the client experience with both Agency and Carrier self-service features. Check them out here >>> Check Out The Modern Insurance Payments Platform Book an Ascend demo at useascend.com/insuranceguys

The market is on recession watch; are they making heads or tails of recent news? In this week's episode, we ponder if commercial real estate will muddle through. We discuss Trepp's latest CMBS delinquency report, noting an increase that could be a blip or a turning point in the recovery. We also dive into several office, retail, and hotel green shoot and crabgrass stories. Tune in now. Episode Notes: • Investors on recession watch (0:23) • CMBS delinquency report (7:28) • Office vacancies (12:07) • Crabgrass for office (16:31) • Office positives (20:23) • Retail update (27:50) • Mall stories (30:37) • Hotel mixed-green (32:49) • Shoutouts (35:14) Questions or comments? Contact us at podcast@trepp.com. Follow Trepp: Twitter: www.twitter.com/TreppWire LinkedIn: www.linkedin.com/company/trepp-llc Facebook: www.facebook.com/TreppLLC